Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Amber Purvine

Physician Assistant Oklahoma City, OK Physician Assistant

NPI 1881765808 CMS profile 10673844

1111 N Lee Ave Ste 300, Oklahoma City, OK 73103

Open in the dashboard

General payments

$2,418

124 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Amber Purvine of Oklahoma City, OK is reported in the CMS Open Payments database as having received $2,418 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $150 1
2022 General $1,083 53
2021 General $1,184 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amber Purvine
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Amber Purvine were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Amber Purvine Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,184 $132 $37–$438 $132
2022 $1,083 $155 $48–$522 $149
2023 $150 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. AstraZeneca Pharmaceuticals LP $437 20 payments
  2. Regeneron Healthcare Solutions, Inc. $228 7 payments
  3. GlaxoSmithKline, LLC. $218 20 payments
  4. Sanofi-Aventis U.S. LLC $182 8 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $170 8 payments
  6. OptiNose US, Inc. $152 12 payments
  7. Zimmer Biomet Holdings, Inc. $150 1 payment
  8. Novartis Pharmaceuticals Corporation $134 9 payments
  9. kaleo, Inc. $130 6 payments
  10. AbbVie, Inc. $101 5 payments
  11. Other $515 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $2,346 122 payments
  2. Education $72 2 payments
Products named General payments · program years 2021–2023
  1. FASENRA $323 12 payments
  2. BREZTRI $229 7 payments
  3. DUPIXENT Inflammation And Immunology $228 7 payments
  4. DUPIXENT Immunology $204 9 payments
  5. TRELEGY ELLIPTA $154 16 payments
  6. Xhance $152 12 payments
  7. GPS III PLATELET CONCENTRATION SYSTEM $150 1 payment
  8. FARXIGA $135 2 payments
  9. XOLAIR $134 9 payments
  10. AUVI-Q $130 6 payments
  11. Other $944 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record